Sean Glenn, PhD

Assistant Professor of Oncology
Center for Personalized Medicine
Director, Genomics Shared Resource
Roswell Park Comprehensive Cancer Center
Director, Research and Development
OmniSeq Precision Medicine Technology
Special Interests: 
Understanding the genetic fingerprint of metastatic disease
Animal models for study of cancer and metastasis (mouse/woodchuck)
Pancreatic neuroEndocrine disease-Development and investigation of a novel mouse model to study cancer progression from primary disease through circulating tumor cell (CTC) involvement to metastasis
Advanced genomic technologies for the study of cancer: Next-Generation Sequencing (NGS) including single-cell sequencing for study of CTCs
Development of novel clinical approaches to identify actionable mutations from bio-fluids (CTCs, cfDNA/RNA) for diagnosis, prognosis, and treatment

Biography

I received a Bachelor’s of Science in Biology from the State University of New York at Buffalo where I studied the RIP function in Neurospora crassa which is a duplication and mutation event localized to the premeiotic cells of the life cycle. I then went on to earn a Master’s of Science from the University at Buffalo focusing on transcriptional regulation of genes responsible for vascular development.

Furthermore, I received a PhD in Molecular and Cellular Biology from the Roswell Park Comprehensive Cancer Center Division of the University of Buffalo where, in the laboratory of Dr. Kenneth W. Gross, I developed a mouse model that mimics human metastatic pancreatic neuroendocrine carcinoma. This model, coupled with NGS technology, is a powerful tool for studying the cooperating mutations responsible for the evolution of metastatic disease including the identification and the role circulating tumor cells play in the progression of this process. This model also offers great promise for studying the pharmaceutical intervention of the metastatic phenotype.

As an Assistant Member in the MCB department, coupled with the dual role I possess as Director of Roswell Park’s Genomics Shared Resource and as OmniSeq’s Director of R&D, affords me a unique ability to transition basic research concepts, findings, and technologies into translational practices with the development of new clinical tests that will be added to OmniSeq’s portfolio.

Background

Education and Training: 
2014 - PhD - Molecular and Cellular Biology – State University of New York at Buffalo, Buffalo, NY
2002 - MS - Natural Sciences - State University of New York at Buffalo, Buffalo, NY